Skip to content
naulon

No retraction, correction or concern found when last checked on Nov 2, 2026.

Extracellular membrane vesicles from umbilical cord blood‐derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning

Lotta Kilpinen, Ulla Impola, Lotta Sankkila and 11 more

Journal of Extracellular Vesicles · 2013 · CC BY-NC

doi:10.3402/jev.v2i0.21927

Abstract

Background Mesenchymal stromal cells (MSC) are shown to have a great therapeutic potential in many immunological disorders. Currently the therapeutic effect of MSCs is considered to be mediated via paracrine interactions with immune cells. Umbilical cord blood is an attractive but still less studied source of MSCs. We investigated the production of extracellular membrane vesicles (MVs) from human umbilical cord blood derived MSCs (hUCBMSC) in the presence (MVstim) or absence (MVctrl) of inflammatory stimulus. Methods hUCBMSCs were cultured in serum free media with or without IFN‐γ and MVs were collected from conditioned media by ultracentrifugation. The protein content of MVs were analyzed by mass spectrometry. Hypoxia induced acute kidney injury rat model was used to analyze the in vivo therapeutic potential of MVs and T‐cell proliferation and induction of regulatory T cells were analyzed by co‐culture assays. Results Both MVstim and MVctrl showed similar T‐cell modulation activity in vitro , but only MVctrls were able to protect rat kidneys from reperfusion injury in vivo. To clarify this difference in functionality we made a comparative mass spectrometric analysis of the MV protein contents. The IFN‐γ stimulation induced dramatic changes in the protein content of the MVs. Complement factors (C3, C4A, C5) and lipid binding proteins (i.e apolipoproteins) were only found in the MVctrls, whereas the MVstim contained tetraspanins (CD9, CD63, CD81) and more complete proteasome complex accompanied with MHCI. We further discovered that differently produced MV pools contained specific Rab proteins suggesting that same cells, depending on external signals, produce vesicles originating from different intracellular locations. Conclusions We demonstrate by both in vitro and in vivo models accompanied with a detailed analysis of molecular characteristics that inflammatory conditioning of MSCs influence on the protein content and functional properties of MVs revealing the complexity of the MSC paracrine regulation.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 87

  1. 1.

    Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269-88.

    Not in our library10.1111/j.1365-2141.1967.tb08741.x

  2. 2.

    Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20:1487-95.

    Not in our library10.1038/sj.leu.2404296

  3. 3.

    György B, Módos K, Pállinger É, Pálóczi K, Pásztói M, Misják P, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood. 2011;117:e39-48.

    Not in our library10.1182/blood-2010-09-307595

  4. 4.

    Van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64:676-705.

    Not in our library10.1124/pr.112.005983

  5. 5.

    Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-9.

    Not in our library10.1038/ncb1596

  6. 6.

    Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013;22:772-80.

    Not in our library10.1089/scd.2012.0266

  7. 7.

    Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581-93.

    Not in our library10.1038/nri2567

  8. 8.

    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86.

    Not in our library10.1016/s0140-6736(08)60690-x

  9. 9.

    Dalal J, Gandy K, Domen J. Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr Res. 2012;71:445-51.

    Not in our library10.1038/pr.2011.56

  10. 10.

    MacDonald GIA, Augello A, De Bari C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:2547-57.

    Not in our library10.1002/art.30474

  11. 11.

    Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-43.

    Not in our library10.1182/blood.v99.10.3838

  12. 12.

    English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156:149-60.

    Not in our library10.1111/j.1365-2249.2009.03874.x

  13. 13.

    Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD, et al. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol. 2009;39:800-9.

    Not in our library10.1002/eji.200838729

  14. 14.

    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815-22.

    Not in our library10.1182/blood-2004-04-1559

  15. 15.

    Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-21.

    Not in our library10.1182/blood-2003-11-3909

  16. 16.

    He J, Wang Y, Sun S, Yu M, Wang C, Pei X, et al. Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrology. 2012;17:493-500.

    Not in our library10.1111/j.1440-1797.2012.01589.x

  17. 17.

    Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26:1474-83.

    Not in our library10.1093/ndt/gfr015

  18. 18.
  19. 19.

    Togel FE, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol. 2010;6:179-83.

    Not in our library10.1038/nrneph.2009.229

  20. 20.

    Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron. 2002;90:133-8.

    Not in our library10.1159/000049032

  21. 21.

    Ascon DB, Lopez-Briones S, Liu M, Ascon M, Savransky V, Colvin RB, et al. Phenotypic and functional characterization of kidney-infiltrating lymphocytes in renal ischemia reperfusion injury. J Immunol. 2006;177:3380-7.

    Not in our library10.4049/jimmunol.177.5.3380

  22. 22.

    Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int. 2010;77:771-80.

    Not in our library10.1038/ki.2010.12

  23. 23.

    Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ, Agreda P, Satpute SR, et al. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009;76:717-29.

    Not in our library10.1038/ki.2009.259

  24. 24.

    Asanuma H, Meldrum DR, Meldrum KK. Therapeutic applications of mesenchymal stem cells to repair kidney injury. J Urol. 2010;184:26-33.

    Not in our library10.1016/j.juro.2010.03.050

  25. 25.

    Cantaluppi V, Gatti S, Medica D, Figliolini F, Bruno S, Deregibus MC, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. 2012;82:412-27.

    Not in our library10.1038/ki.2012.105

  26. 26.

    DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795-806.

    Not in our library10.1089/ten.tea.2008.0630

  27. 27.

    Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141-50.

    Not in our library10.1016/j.stem.2007.11.014

  28. 28.

    English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110:91-100.

    Not in our library10.1016/j.imlet.2007.04.001

  29. 29.

    Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-63.

    Not in our library10.1111/j.1365-2249.2007.03422.x

  30. 30.

    Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745-55.

    Not in our library10.1002/eji.200738129

  31. 31.

    Krampera M. Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia. 2011;25:1408-14.

    Not in our library10.1038/leu.2011.108

  32. 32.

    Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFN-gamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18:846-57.

    Not in our library10.1038/cr.2008.80

  33. 33.

    Bieback K, Kern S, Kocaomer A, Ferlik K, Bugert P. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng. 2008;18(1 Suppl):71-6.

    Not in our library

  34. 34.

    Najar M, Raicevic G, Boufker HI, Kazan HF, Bruyn CD, Meuleman N, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 2010;264:171-9.

    Not in our library10.1016/j.cellimm.2010.06.006

  35. 35.

    Hsiao ST, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012;21:2189-203.

    Not in our library10.1089/scd.2011.0674

  36. 36.
  37. 37.

    Laitinen A, Nystedt J, Laitinen S. The isolation and culture of human cord blood-derived mesenchymal stem cells under low oxygen conditions. Methods Mol Biol. 2011;698:63-73.

    Not in our library10.1007/978-1-60761-999-4_6

  38. 38.

    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.

    Not in our library10.1080/14653240600855905

  39. 39.

    O'Connell KL, Stults JT. Identification of mouse liver proteins on two-dimensional electrophoresis gels by matrix-assisted laser desorption/ionization mass spectrometry of in situ enzymatic digests. Electrophoresis. 1997;18:349-59.

    Not in our library10.1002/elps.1150180309

  40. 40.

    Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1:2856-60.

    Not in our library10.1038/nprot.2006.468

  41. 41.

    Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.

    Not in our library10.1038/nprot.2008.211

  42. 42.

    Lempiäinen J, Finckenberg P, Levijoki J, Mervaala E. AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney. Br J Pharmacol. 2012;166:1905-15.

    Not in our library10.1111/j.1476-5381.2012.01895.x

  43. 43.

    Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 2012;40:D1241-4.

    Not in our library10.1093/nar/gkr828

  44. 44.

    Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26:212-22.

    Not in our library10.1634/stemcells.2007-0554

  45. 45.

    Ianni MD, Beatrice DP, Ioanni MD, Moretti L, Bonifacio E, Cecchini D, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309-18.

    Not in our library10.1016/j.exphem.2007.11.007

  46. 46.

    Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T-cells. J Immunol. 2008;181:3933-46.

    Not in our library10.4049/jimmunol.181.6.3933

  47. 47.

    Engela AU, Hoogduijn MJ, Boer K, Litjens NHR, Betjes MGH, Weimar W, et al. Human adipose-tissue derived mesenchymal stem cells induce functional de novo regulatory T-cells with methylated FOXP3 gene DNA. Clin Exp Immunol. 2013;173:343-54.

    Not in our library10.1111/cei.12120

  48. 48.

    Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell–cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol. 2011;41:2840-51.

    Not in our library10.1002/eji.201141499

  49. 49.

    Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302-12.

    Not in our library10.4049/jimmunol.0902007

  50. 50.

    Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein Kinase R. Stem Cells. 2009;27:909-19.

    Not in our library10.1002/stem.7

  51. 51.

    Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214-22.

    Not in our library10.1016/j.scr.2009.12.003

  52. 52.

    Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012;30:1556-64.

    Not in our library10.1002/stem.1129

  53. 53.

    Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid A, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012;147:47-54.

    Not in our library10.1016/j.imlet.2012.06.001

  54. 54.
  55. 55.

    Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053-67.

    Not in our library10.1681/asn.2008070798

  56. 56.
  57. 57.

    Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121:4210-21.

    Not in our library10.1172/jci45161

  58. 58.

    Alexandre CS, Volpini RA, Shimizu MH, Sanches TR, Semedo P, di Jura VL, et al. Lineage-negative bone marrow cells protect against chronic renal failure. Stem Cells. 2009;27:682-92.

    Not in our library10.1634/stemcells.2008-0496

  59. 59.

    Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Romanazzi G, Sanavio F, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007;72:430-41.

    Not in our library10.1038/sj.ki.5002334

  60. 60.

    Behr L, Hekmati M, Lucchini A, Houcinet K, Faussat AM, Borenstein N, et al. Evaluation of the effect of autologous mesenchymal stem cell injection in a large-animal model of bilateral kidney ischaemia reperfusion injury. Cell Prolif. 2009;42:284-97.

    Not in our library10.1111/j.1365-2184.2009.00591.x

  61. 61.

    Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6:412-22.

    Not in our library10.2215/cjn.04950610

  62. 62.

    Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 2006;70:121-9.

    Not in our library10.1038/sj.ki.5001521

  63. 63.

    Lindoso RS, Araujo DS, Adao-Novaes J, Mariante RM, Verdoorn KS, Fragel-Madeira L, et al. Paracrine interaction between bone marrow-derived stem cells and renal epithelial cells. Cell Physiol Biochem. 2011;28:267-78.

    Not in our library10.1159/000331739

  64. 64.

    Hu J, Zhang L, Wang N, Ding R, Cui S, Zhu F, et al. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int. 2013;84:521-31.

    Not in our library10.1038/ki.2013.114

  65. 65.

    Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383-96.

    Not in our library10.1038/nri3209

  66. 66.

    Lepelletier Y, Lecourt S, Renand A, Arnulf B, Vanneaux V, Fermand JP, et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev. 2010;19:1075-9.

    Not in our library10.1089/scd.2009.0212

  67. 67.

    Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. 2010;116:3770-9.

    Not in our library10.1182/blood-2010-02-270777

  68. 68.

    Sioud M, Mobergslien A, Boudabous A, Floisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol. 2011;38:385-90.

    Not in our library10.3892/ijo.2010.869

  69. 69.

    Garín MI, Chu C, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4 + CD25+ T cells. Blood. 2007;109:2058-65.

    Not in our library10.1182/blood-2006-04-016451

  70. 70.

    Sattler C, Steinsdoerfer M, Offers M, Fischer E, Schierl R, Heseler K, et al. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant. 2011;20:1221-30.

    Not in our library10.3727/096368910x546553

  71. 71.

    Campioni D, Rizzo R, Stignani M, Melchiorri L, Ferrari L, Moretti S, et al. A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry B Clin Cytom. 2009;76:225-30.

    Not in our library10.1002/cyto.b.20461

  72. 72.

    Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-65.

    Not in our library10.1084/jem.20062512

  73. 73.

    Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331-42.

    Not in our library10.1172/jci38702

  74. 74.

    Tsukamoto H, Chernogorova P, Ayata K, Gerlach UV, Rughani A, Ritchey JW, et al. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood. 2012;119:4554-64.

    Not in our library10.1182/blood-2011-09-375899

  75. 75.

    Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513-25.

    Not in our library10.1038/nrm2728

  76. 76.

    Pfeffer SR. Two Rabs for exosome release. Nat Cell Biol. 2010;12:3-4.

    Not in our library10.1038/ncb0110-3

  77. 77.

    Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12:19-30.

    Not in our library10.1038/ncb2000

  78. 78.

    Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91:119-49.

    Not in our library10.1152/physrev.00059.2009

  79. 79.

    Bultema JJ, Di Pietro SM. Cell type-specific Rab32 and Rab38 cooperate with the ubiquitous lysosome biogenesis machinery to synthesize specialized lysosome-related organelles. Small GTPases. 2013;4:16-21.

    Not in our library10.4161/sgtp.22349

  80. 80.
  81. 81.

    Goldenberg NM, Grinstein S, Silverman M. Golgi-bound Rab34 is a novel member of the secretory pathway. Mol Biol Cell. 2007;18:4762-71.

    Not in our library10.1091/mbc.e06-11-0991

  82. 82.

    Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003;278:10963-72.

    Not in our library10.1074/jbc.m207550200

  83. 83.

    Kim CH, Wu W, Wysoczynski M, Abdel-Latif A, Sunkara M, Morris A, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia. 2012;26:106-16.

    Not in our library10.1038/leu.2011.185

  84. 84.

    Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med. 1998;188:2313-20.

    Not in our library10.1084/jem.188.12.2313

  85. 85.

    Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol. 2009;156:303-11.

    Not in our library10.1111/j.1365-2249.2009.03896.x

  86. 86.

    Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang Q, Lapergue B, et al. HDL and endothelial protection. Br J Pharmacol. 2013;169:493-511.

    Not in our library10.1111/bph.12174

  87. 87.

    Shi N, Wu MP. Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats. J Biomed Sci. 2008;15:577-83.

    Not in our library10.1007/s11373-008-9258-7

Cited by papers we hold 15

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.